We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Pulls Back From Multi-Billion Dollar Development Deal With Galapagos for Rheumatoid Arthritis Drug
Gilead Pulls Back From Multi-Billion Dollar Development Deal With Galapagos for Rheumatoid Arthritis Drug
Gilead Sciences has downgraded its development pact with Belgian drugmaker Galapagos after deciding to no longer pursue FDA approval for its rheumatoid arthritis (RA) drug Jyseleca (filgotinib).